The successful developments of Lutetium-177 (Lu-177) dotatate and Lu-177 prostate-specific membrane antigen (PSMA)-617 in advanced neuroendocrine tumor [126] and castration-resistant prostate cancer [127], respectively, have brought targeted radionuclide therapy to daily oncology practice. This evidence concerns the gene FOLH1 and neuroendocrine neoplasm.